Dr. Da-Yong LU, born in July, 1962 in Shanghai. oc/professor; ed/ph D Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 2005, MS, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 1986, BS, Shanghai Medical University (Now Fudan University affiliated) in1982; He is working as an associated professor at Shanghai University, Shanghai200444, PR China. Undergo the studies of cancer pathology, biochemistry, pharmacology and clinical therapeutics, especially on the pharmacological studies of new Chinese anticancer agent probimane and MST-16 and antimetastatic targets of fibrinogen and sialic acids and individualized cancer chemotherapy (ICC) since 1982. His interest is focused on the basic studies of cancer biology, pathology, treatment, origins of life, human suicide study, metabolic disease, orthopaedic diseases, viral disease treatment and other field of science disciplines. He is serving as an editorial member of several reputed international journals. He was the first author of more than 150 original scientific articles in international journals and three books published by UK, US and Germany-based publication companies.
Dr. Da-Yong LU research interests are Pharmacological and clinical study of anticancer drugs and personalized medicine. Drug developments Clinical treatment of metabolic diseases, such as type 2 diabetes, osteoporosis and obesity. Clinical diagnosis and treatment of human suicide. Human viral infection diseases and drug developments, such as HIV, avian flu, Ebola and seasonal flu Traditional Chinese medicine.